PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

With tumor reduction seen in 48% of the 33 patients studied, the combination treatment had an overall response rate of 21% in ...

Jazz Pharmaceuticals announced that the FDA has approved ZIIHERA® (zanidatamab-hrii) on an accelerated basis for the treatment ...

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.

The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

China National Medical Products Administration (NMPA) has approved MSD’s KEYTRUDA for treating certain non-small cell lung cancer (NSCLC).

Johnson & Johnson JNJ announced that the FDA has issued a complete response letter (“CRL”) to its biologics license ...

Among the heavily pretreated NSCLC EGFR wild-type patients, the combination therapy demonstrated an overall response rate of 21 percent, and a disease control rate of 76 percent. Moreover, tumor ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of ...